Adverum Biotechnologies Inc logo

ADVM - Adverum Biotechnologies Inc News Story

$12.38 -0.5  -3.5%

Last Trade - 18/09/20

Mid Cap
Market Cap £912.0m
Enterprise Value £695.1m
Revenue £194k
Position in Universe 2253rd / 6396

BUZZ-RBC sees potential in gene, cell therapies; begins coverage of eight biotechs

Wed 13th May, 2020 9:31am
** RBC Capital Markets starts coverage of eight biotech
stocks focusing on RNAi, a form of gene silencing used to treat
rare bleeding disorders, among others
    ** RBC calls the space, which includes gene and cell
therapies, "the new wave of biotech innovation"
    ** There could be 10 marketing approvals in next 1-2 years,
with more than 1,000 clinical trials ongoing across oncology,
cardiovascular, respiratory, CNS and rare disease areas - RBC 
    ** Brokerage says revenue generation from already approved
treatments plus potential near-term approvals could total $21
bln by 2025, according to consensus estimates 
    ** RBC starts coverage of six biotechs with "outperform"
rating, while settles on "sector perform" for the other two,
with PTs as follows:

 Company Name                             Price   Rating
 Dicerna Pharmaceuticals Inc  DRNA.O      $35     Outperform
 Adverum Biotechnologies Inc  ADVM.O      $24     Outperform
 bluebird bio Inc  BLUE.O                 $100    Outperform
 Ionis Pharmaceuticals Inc  IONS.O        $71     Outperform
 Arrowhead Pharmaceuticals Inc  ARWR.O    $62     Outperform
 Homology Medicines Inc  FIXX.O           $30     Outperform
 Alnylam Pharmaceuticals Inc  ALNY.O      $150    Sector Perform
 REGENXBIO Inc  RGNX.O                    $42     Sector Perform
 (Reporting by Aakash Jagadeesh Babu in Bengaluru)
 ((; Twitter: @JagadeeshAakash))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.